Healthcare
•3734 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3734)
| Company | Market Cap | Price |
|---|---|---|
|
FLGT
Fulgent Genetics, Inc.
Company operates clinical lab chains providing diagnostic testing.
|
$502.64M |
$16.29
+0.99%
|
|
VREX
Varex Imaging Corporation
Core Medical Imaging category representing imaging hardware and components used in medical devices.
|
$500.82M |
$11.99
+3.41%
|
|
KMDA
Kamada Ltd.
Biosimilar product distribution is a key existing business line for Kamada's expanded portfolio.
|
$488.22M |
$8.48
+2.91%
|
|
ESPR
Esperion Therapeutics, Inc.
Directly sells/markets cardiovascular drugs (NEXLETOL, NEXLIZET).
|
$487.69M |
$2.04
-0.73%
|
|
DNA
Ginkgo Bioworks Holdings, Inc.
Antibody Discovery Platform reflects the antibody-focused tools and services offered.
|
$486.54M |
$8.04
+1.13%
|
|
VALN
Valneva SE
Valneva directly manufactures and sells vaccines (e.g., VLA15 Lyme vaccine, IXCHIQ chikungunya vaccine, IXIARO, DUKORAL) and is advancing multiple vaccine candidates, making vaccines its core product category.
|
$483.94M |
$5.96
-0.25%
|
|
RGNX
REGENXBIO Inc.
Core product category: gene therapy using NAV AAV platform.
|
$480.41M |
$9.49
+3.26%
|
|
BNTC
Benitec Biopharma Inc.
BB-301 is an AAV-based gene therapy leveraging gene silencing and wildtype replacement, aligning with Gene Therapy.
|
$476.78M |
$13.99
+3.94%
|
|
STTK
Shattuck Labs, Inc.
SL-325 is a monoclonal antibody targeting DR3, making Monoclonal Antibody Therapeutics a direct product category.
|
$476.50M |
$7.50
+2.11%
|
|
MYGN
Myriad Genetics, Inc.
Companion diagnostics—biomarker-based tests that stratify patients for targeted therapies; aligns with Myriad's genetic tests.
|
$473.53M |
$5.08
+1.70%
|
|
ZVRA
Zevra Therapeutics, Inc.
Zevra focuses on rare-disease therapeutics (NPC, UCD, VEDS) and related pipeline assets, core to rare disease biotech.
|
$466.48M |
$8.48
+2.05%
|
|
EBS
Emergent BioSolutions Inc.
EBS directly develops and manufactures vaccines and vaccine-derived MCMs (BioThrax, ACAM2000, TEMBEXA) for government/public health programs.
|
$462.70M |
$8.81
+2.20%
|
|
ASMB
Assembly Biosciences, Inc.
Assembly Biosciences develops small-molecule antiviral therapeutics, including HSV helicase-primase inhibitors, HDV entry inhibitors, HBV capsid assembly modulators, and NNPI programs.
|
$462.49M |
$29.10
-0.75%
|
|
ACRS
Aclaris Therapeutics, Inc.
Company's focus is on immuno-inflammatory diseases, aligning with Immunology Therapeutics.
|
$460.47M |
$4.25
+6.78%
|
|
FULC
Fulcrum Therapeutics, Inc.
Fulcrum's lead asset pociredir is an oral small molecule therapeutic intended to induce HbF in SCD.
|
$448.64M |
$8.29
+3.82%
|
|
AVIR
Atea Pharmaceuticals, Inc.
Atea's lead program comprises antiviral small-molecule therapeutics targeting HCV.
|
$448.45M |
$5.74
+0.61%
|
|
ANGO
AngioDynamics, Inc.
Core product category: vascular intervention devices, including Auryon, AlphaVac, and AngioVac.
|
$447.62M |
$10.87
+3.87%
|
|
VSTM
Verastem, Inc.
Company is a oncology-focused biotech developing and commercializing cancer therapeutics.
|
$439.39M |
$6.58
+3.71%
|
|
PRTC
PureTech Health plc
Glyph platform is a drug-delivery technology enabling oral administration of therapies.
|
$438.14M |
$18.09
-0.71%
|
|
CYH
Community Health Systems, Inc.
CYH directly provides hospital inpatient and outpatient care services through a network of hospitals and related facilities.
|
$437.72M |
$3.17
+1.12%
|
|
KYTX
Kyverna Therapeutics, Inc.
KYTX's lead and pipeline CAR-T products (KYV-101, KYV-102, KYV-201) are autologous/allogeneic CD19 CAR-T cell therapies, a direct cell therapy product category.
|
$434.90M |
$9.92
+4.09%
|
|
NGNE
Neurogene Inc.
NGNE directly develops gene therapy candidates (NGN-401) and uses a gene therapy platform, matching Biotech - Gene Therapy.
|
$431.39M |
$27.85
+8.66%
|
|
VNDA
Vanda Pharmaceuticals Inc.
Fanapt and other marketed/potential small-molecule therapies (e.g., Tradipitant) are oral small molecule therapeutics.
|
$429.63M |
$7.26
+1.47%
|
|
AUTL
Autolus Therapeutics plc
Core product: obe-cel CAR-T cell therapy (cell therapy) for rr B-ALL.
|
$425.83M |
$1.60
-0.62%
|
|
FBRX
Forte Biosciences, Inc.
FB102 is a monoclonal antibody therapeutic targeting CD122, directly matching Monoclonal Antibody Therapeutics.
|
$424.91M |
$33.76
+7.41%
|
|
RCKT
Rocket Pharmaceuticals, Inc.
Direct gene therapy platform encompassing ex vivo LV and in vivo AAV modalities.
|
$423.15M |
$3.92
+0.38%
|
|
KIDS
OrthoPediatrics Corp.
Directly manufactures pediatric orthopedic implants and devices (plates, screws, growing rods, braces), the core product category for the company.
|
$420.05M |
$16.73
+1.21%
|
|
AUNA
Auna S.A.
AUNA offers health insurance plans integrated with care delivery (OncoSalud), constituting health insurance services.
|
$415.71M |
$5.62
+1.81%
|
Showing page 18 of 38 (3734 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
